Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Ipragliflozin

Generic Name: Ipragliflozin

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₁FO_₅S

CAS Number: 761423-87-4

Unique Ingredient Identifier: 3N2N8OOR7X

Overview

Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.

Background

Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

Phase 4

Terminated

Posted: 2017/04/18

Sponsor:Astellas Pharma Kore...

ID:NCT03118713

Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

Phase 3

Completed

Posted: 2017/03/09

Sponsor:Seoul National Unive...

ID:NCT03076112

A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus

Phase 3

Completed

Posted: 2016/09/13

Sponsor:Astellas Pharma Inc

ID:NCT02897219

Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone

Phase 4

Completed

Posted: 2016/08/23

Sponsor:Yonsei University

ID:NCT02875821

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

Phase 4

Completed

Posted: 2016/07/28

Sponsor:Astellas Pharma Inc

ID:NCT02847091

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy